Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study

{ 'DOI': '10.1016/s1473-3099(22)00507-2', 'ISSN': ['1473-3099'], 'URL': 'http://dx.doi.org/10.1016/S1473-3099(22)00507-2', 'alternative-id': ['S1473309922005072'], 'assertion': [ {'label': 'This article is maintained by', 'name': 'publisher', 'value': 'Elsevier'}, { 'label': 'Article Title', 'name': 'articletitle', 'value': 'Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in ' 'hospitalised patients with COVID-19 without supplemental oxygen requirement on ' "admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study"}, { 'label': 'Journal Title', 'name': 'journaltitle', 'value': 'The Lancet Infectious Diseases'}, { 'label': 'CrossRef DOI link to publisher maintained version', 'name': 'articlelink', 'value': 'https://doi.org/10.1016/S1473-3099(22)00507-2'}, { 'label': 'CrossRef DOI link to the associated document', 'name': 'associatedlink', 'value': 'https://doi.org/10.1016/S1473-3099(22)00522-9'}, {'label': 'Content Type', 'name': 'content_type', 'value': 'article'}, { 'label': 'Copyright', 'name': 'copyright', 'value': '© 2022 Elsevier Ltd. All rights reserved.'}], 'author': [ {'affiliation': [], 'family': 'Wong', 'given': 'Carlos K H', 'sequence': 'first'}, {'affiliation': [], 'family': 'Au', 'given': 'Ivan C H', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Lau', 'given': 'Kristy T K', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Lau', 'given': 'Eric H Y', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Cowling', 'given': 'Benjamin J', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Leung', 'given': 'Gabriel M', 'sequence': 'additional'}], 'container-title': 'The Lancet Infectious Diseases', 'container-title-short': 'The Lancet Infectious Diseases', 'content-domain': { 'crossmark-restriction': True, 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'em-consulte.com', 'thelancet.com', 'elsevier.com', 'sciencedirect.com']}, 'created': {'date-parts': [[2022, 8, 24]], 'date-time': '2022-08-24T22:34:53Z', 'timestamp': 1661380493000}, 'deposited': { 'date-parts': [[2022, 8, 24]], 'date-time': '2022-08-24T22:35:19Z', 'timestamp': 1661380519000}, 'indexed': {'date-parts': [[2022, 8, 24]], 'date-time': '2022-08-24T23:12:45Z', 'timestamp': 1661382765673}, 'is-referenced-by-count': 1, 'issued': {'date-parts': [[2022, 8]]}, 'language': 'en', 'license': [ { 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 8, 1]], 'date-time': '2022-08-01T00:00:00Z', 'timestamp': 1659312000000}}], 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1473309922005072?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1473309922005072?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'prefix': '10.1016', 'published': {'date-parts': [[2022, 8]]}, 'published-print': {'date-parts': [[2022, 8]]}, 'publisher': 'Elsevier BV', 'reference': [ { 'DOI': '10.3389/fphar.2022.816429', 'article-title': 'Effectiveness of antiviral therapy in highly-transmissible variants of ' 'SARS-CoV-2: a modeling and simulation study', 'author': 'Schöning', 'doi-asserted-by': 'crossref', 'journal-title': 'Front Pharmacol', 'key': '10.1016/S1473-3099(22)00507-2_bib5', 'volume': '13', 'year': '2022'}, { 'DOI': '10.1016/j.dsx.2022.102396', 'article-title': 'An updated practical guideline on use of molnupiravir and comparison ' 'with agents having emergency use authorization for treatment of ' 'COVID-19', 'author': 'Singh', 'doi-asserted-by': 'crossref', 'journal-title': 'Diabetes Metab Syndr', 'key': '10.1016/S1473-3099(22)00507-2_bib6', 'volume': '16', 'year': '2022'}, { 'DOI': '10.3389/fimmu.2022.855496', 'article-title': 'Molnupiravir and its antiviral activity against COVID-19', 'author': 'Tian', 'doi-asserted-by': 'crossref', 'journal-title': 'Front Immunol', 'key': '10.1016/S1473-3099(22)00507-2_bib7', 'volume': '13', 'year': '2022'}, { 'DOI': '10.1136/bmj.o443', 'article-title': "Molnupiravir's authorisation was premature", 'author': 'Brophy', 'doi-asserted-by': 'crossref', 'first-page': 'o443', 'journal-title': 'BMJ', 'key': '10.1016/S1473-3099(22)00507-2_bib8', 'volume': '376', 'year': '2022'}, { 'article-title': 'COVID-19: FDA expert panel recommends authorising molnupiravir but also ' 'voices concerns', 'author': 'Dyer', 'journal-title': 'BMJ', 'key': '10.1016/S1473-3099(22)00507-2_bib9', 'volume': '375', 'year': '2021'}, { 'DOI': '10.1136/bmj.o977', 'article-title': 'Imbalance in baseline characteristics in molnupiravir trials', 'author': 'Hama', 'doi-asserted-by': 'crossref', 'first-page': 'o977', 'journal-title': 'BMJ', 'key': '10.1016/S1473-3099(22)00507-2_bib10', 'volume': '377', 'year': '2022'}, { 'DOI': '10.1016/S1473-3099(22)00119-0', 'article-title': 'Availability of oral antivirals against SARS-CoV-2 infection and the ' 'requirement for an ethical prescribing approach', 'author': 'Dal-Ré', 'doi-asserted-by': 'crossref', 'first-page': 'e231', 'journal-title': 'Lancet Infect Dis', 'key': '10.1016/S1473-3099(22)00507-2_bib11', 'volume': '22', 'year': '2022'}, { 'DOI': '10.1016/j.eclinm.2021.100743', 'article-title': 'Clinical outcomes of different therapeutic options for COVID-19 in two ' 'Chinese case cohorts: a propensity-score analysis', 'author': 'Wong', 'doi-asserted-by': 'crossref', 'journal-title': 'EClinicalMedicine', 'key': '10.1016/S1473-3099(22)00507-2_bib12', 'volume': '32', 'year': '2021'}, { 'DOI': '10.1016/S1473-3099(22)00345-0', 'article-title': 'Vaccine effectiveness of one, two, and three doses of BNT162b2 and ' 'CoronaVac against COVID-19 in Hong Kong: a population-based ' 'observational study', 'author': 'McMenamin', 'doi-asserted-by': 'crossref', 'journal-title': 'Lancet Infect Dis', 'key': '10.1016/S1473-3099(22)00507-2_bib13', 'year': '2022'}, { 'DOI': '10.1001/jamainternmed.2020.6252', 'article-title': 'Association between early treatment with tocilizumab and mortality ' 'among critically ill patients with COVID-19', 'author': 'Gupta', 'doi-asserted-by': 'crossref', 'first-page': '41', 'journal-title': 'JAMA Intern Med', 'key': '10.1016/S1473-3099(22)00507-2_bib17', 'volume': '181', 'year': '2021'}, { 'DOI': '10.1186/s13054-020-03422-3', 'article-title': 'Early corticosteroids are associated with lower mortality in critically ' 'ill patients with COVID-19: a cohort study', 'author': 'Monedero', 'doi-asserted-by': 'crossref', 'first-page': '2', 'journal-title': 'Crit Care', 'key': '10.1016/S1473-3099(22)00507-2_bib18', 'volume': '25', 'year': '2021'}, { 'DOI': '10.1093/aje/kwab028', 'article-title': 'Biases in evaluating the safety and effectiveness of drugs for the ' 'treatment of COVID-19: designing real-world evidence studies', 'author': 'Renoux', 'doi-asserted-by': 'crossref', 'first-page': '1452', 'journal-title': 'Am J Epidemiol', 'key': '10.1016/S1473-3099(22)00507-2_bib19', 'volume': '190', 'year': '2021'}, { 'DOI': '10.1093/cid/ciab631', 'article-title': 'Clinical improvement, outcomes, antiviral activity, and costs ' 'associated with early treatment with remdesivir for patients with ' 'coronavirus disease 2019 (COVID-19)', 'author': 'Wong', 'doi-asserted-by': 'crossref', 'first-page': '1450', 'journal-title': 'Clin Infect Dis', 'key': '10.1016/S1473-3099(22)00507-2_bib20', 'volume': '74', 'year': '2022'}, { 'DOI': '10.1002/sim.4067', 'article-title': 'Multiple imputation using chained equations: issues and guidance for ' 'practice', 'author': 'White', 'doi-asserted-by': 'crossref', 'first-page': '377', 'journal-title': 'Stat Med', 'key': '10.1016/S1473-3099(22)00507-2_bib22', 'volume': '30', 'year': '2011'}, { 'DOI': '10.1177/0962280217713032', 'article-title': 'Propensity score analysis with partially observed covariates: how ' 'should multiple imputation be used?', 'author': 'Leyrat', 'doi-asserted-by': 'crossref', 'first-page': '3', 'journal-title': 'Stat Methods Med Res', 'key': '10.1016/S1473-3099(22)00507-2_bib23', 'volume': '28', 'year': '2019'}, { 'DOI': '10.1002/bimj.200810488', 'article-title': 'Some methods of propensity-score matching had superior performance to ' 'others: results of an empirical investigation and Monte Carlo ' 'simulations', 'author': 'Austin', 'doi-asserted-by': 'crossref', 'first-page': '171', 'journal-title': 'Biom J', 'key': '10.1016/S1473-3099(22)00507-2_bib24', 'volume': '51', 'year': '2009'}, { 'DOI': '10.1093/cid/ciac180', 'article-title': 'Molnupiravir and nirmatrelvir–ritonavir: oral COVID antiviral drugs', 'author': 'Saravolatz', 'doi-asserted-by': 'crossref', 'journal-title': 'Clin Infect Dis', 'key': '10.1016/S1473-3099(22)00507-2_bib25', 'year': '2022'}, { 'DOI': '10.1056/NEJMoa2118542', 'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19', 'author': 'Hammond', 'doi-asserted-by': 'crossref', 'first-page': '1397', 'journal-title': 'N Engl J Med', 'key': '10.1016/S1473-3099(22)00507-2_bib27', 'volume': '386', 'year': '2022'}, { 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients', 'author': 'Jayk Bernal', 'doi-asserted-by': 'crossref', 'first-page': '509', 'journal-title': 'N Engl J Med', 'key': '10.1016/S1473-3099(22)00507-2_bib28', 'volume': '386', 'year': '2022'}, { 'article-title': 'Effectiveness of paxlovid in reducing severe COVID-19 and mortality in ' 'high risk patients', 'author': 'Najjar-Debbiny', 'journal-title': 'Clin Infect Dis', 'key': '10.1016/S1473-3099(22)00507-2_bib29', 'year': '2022'}, { 'article-title': 'Oral nirmatrelvir and severe COVID-19 outcomes during the omicron surge', 'author': 'Arbel', 'journal-title': 'Research Square', 'key': '10.1016/S1473-3099(22)00507-2_bib30', 'year': '2022'}, { 'DOI': '10.1056/EVIDoa2100044', 'article-title': 'Randomized trial of molnupiravir or placebo in patients hospitalized ' 'with COVID-19', 'author': 'Arribas', 'doi-asserted-by': 'crossref', 'journal-title': 'NEJM Evidence', 'key': '10.1016/S1473-3099(22)00507-2_bib31', 'volume': '1', 'year': '2022'}, { 'DOI': '10.7326/M22-0729', 'article-title': 'Effect of molnupiravir on biomarkers, respiratory interventions, and ' 'medical services in COVID-19: a randomized, placebo-controlled trial', 'author': 'Johnson', 'doi-asserted-by': 'crossref', 'journal-title': 'Ann Intern Med', 'key': '10.1016/S1473-3099(22)00507-2_bib32', 'year': '2022'}, { 'DOI': '10.1038/s41422-022-00619-9', 'article-title': 'Reduced interferon antagonism but similar drug sensitivity in omicron ' 'variant compared to delta variant of SARS-CoV-2 isolates', 'author': 'Bojkova', 'doi-asserted-by': 'crossref', 'first-page': '319', 'journal-title': 'Cell Res', 'key': '10.1016/S1473-3099(22)00507-2_bib33', 'volume': '32', 'year': '2022'}, { 'DOI': '10.1038/s41422-022-00618-w', 'article-title': 'SARS-CoV-2 omicron variant is highly sensitive to molnupiravir, ' 'nirmatrelvir, and the combination', 'author': 'Li', 'doi-asserted-by': 'crossref', 'first-page': '322', 'journal-title': 'Cell Res', 'key': '10.1016/S1473-3099(22)00507-2_bib34', 'volume': '32', 'year': '2022'}, { 'DOI': '10.1056/NEJMc2119407', 'article-title': 'Efficacy of antibodies and antiviral drugs against COVID-19 omicron ' 'variant', 'author': 'Takashita', 'doi-asserted-by': 'crossref', 'first-page': '995', 'journal-title': 'N Engl J Med', 'key': '10.1016/S1473-3099(22)00507-2_bib35', 'volume': '386', 'year': '2022'}, { 'DOI': '10.1016/j.antiviral.2022.105252', 'article-title': 'Remdesivir, molnupiravir and nirmatrelvir remain active against ' 'SARS-CoV-2 omicron and other variants of concern', 'author': 'Vangeel', 'doi-asserted-by': 'crossref', 'journal-title': 'Antiviral Res', 'key': '10.1016/S1473-3099(22)00507-2_bib36', 'volume': '198', 'year': '2022'}, { 'DOI': '10.1016/j.bmcl.2022.128629', 'article-title': 'Main protease mutants of SARS-CoV-2 variants remain susceptible to ' 'nirmatrelvir', 'author': 'Ullrich', 'doi-asserted-by': 'crossref', 'journal-title': 'Bioorg Med Chem Lett', 'key': '10.1016/S1473-3099(22)00507-2_bib37', 'volume': '62', 'year': '2022'}, { 'DOI': '10.1056/NEJMc2201933', 'article-title': 'Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant ' 'BA.2', 'author': 'Takashita', 'doi-asserted-by': 'crossref', 'first-page': '1475', 'journal-title': 'N Engl J Med', 'key': '10.1016/S1473-3099(22)00507-2_bib38', 'volume': '386', 'year': '2022'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib39', 'series-title': 'Hetero announces interim clinical results from phase III clinical trials ' 'of molnupiravir conducted in India', 'year': '2021'}, { 'DOI': '10.1126/scitranslmed.abl7430', 'article-title': 'A phase 2a clinical trial of molnupiravir in patients with COVID-19 ' 'shows accelerated SARS-CoV-2 RNA clearance and elimination of ' 'infectious virus', 'author': 'Fischer', 'doi-asserted-by': 'crossref', 'journal-title': 'Sci Transl Med', 'key': '10.1016/S1473-3099(22)00507-2_bib40', 'volume': '14', 'year': '2022'}, { 'DOI': '10.3389/fphar.2022.939573', 'article-title': 'Antiviral efficacy and safety of molnupiravir against omicron variant ' 'infection: a randomized controlled clinical trial', 'author': 'Zou', 'doi-asserted-by': 'crossref', 'journal-title': 'Front Pharmacol', 'key': '10.1016/S1473-3099(22)00507-2_bib42', 'volume': '13', 'year': '2022'}, { 'article-title': 'Oral antivirals for the prevention and treatment of SARS-CoV-2 ' 'infection', 'author': 'Soriano', 'first-page': '41', 'journal-title': 'AIDS Rev', 'key': '10.1016/S1473-3099(22)00507-2_bib43', 'volume': '24', 'year': '2022'}, { 'DOI': '10.1016/j.dsx.2021.102329', 'article-title': 'Molnupiravir in COVID-19: a systematic review of literature', 'author': 'Singh', 'doi-asserted-by': 'crossref', 'journal-title': 'Diabetes Metab Syndr', 'key': '10.1016/S1473-3099(22)00507-2_bib46', 'volume': '15', 'year': '2021'}, { 'DOI': '10.1002/em.22471', 'article-title': 'Human genetic risk of treatment with antiviral nucleoside analog drugs ' 'that induce lethal mutagenesis: the special case of molnupiravir', 'author': 'Waters', 'doi-asserted-by': 'crossref', 'first-page': '37', 'journal-title': 'Environ Mol Mutagen', 'key': '10.1016/S1473-3099(22)00507-2_bib47', 'volume': '63', 'year': '2022'}, { 'DOI': '10.1093/infdis/jiab247', 'article-title': 'β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis ' 'but is also mutagenic to mammalian cells', 'author': 'Zhou', 'doi-asserted-by': 'crossref', 'first-page': '415', 'journal-title': 'J Infect Dis', 'key': '10.1016/S1473-3099(22)00507-2_bib48', 'volume': '224', 'year': '2021'}, { 'DOI': '10.3390/ijms23073507', 'article-title': 'Potential resistance of SARS-CoV-2 main protease (Mpro) against ' 'protease inhibitors: lessons learned from HIV-1 protease', 'author': 'Mótyán', 'doi-asserted-by': 'crossref', 'journal-title': 'Int J Mol Sci', 'key': '10.1016/S1473-3099(22)00507-2_bib49', 'volume': '23', 'year': '2022'}], 'reference-count': 37, 'references-count': 37, 'relation': {}, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1473309922005072'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases'], 'subtitle': [], 'title': 'Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised ' "patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's " 'omicron BA.2 wave: a retrospective cohort study', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy'}